000			03150nam a22003735i 4500
001			86076
003			ES-MaUEC
005			20230202104949.0
007			cr nn 008mamaa
008			160610s2016 gw | s |||| 0|eng d
020			_a9783319342115
040			_aES-MaUEC
050		4	_aRC268.4 _b2016 EB
245	0	0	_aPI3K-mTOR in Cancer and Cancer Therapy _cedited by Nandini Dey, Pradip De, Brian Leyland-Jones
260			_aCham _bSpringer International Publishing _bImprint _bHumana Press _c2016
300			_a1 recurso en línea (XXIV, 294 p.) 31 il. col.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aCancer Drug Discovery and Development _x2196-9906
520			_aIn the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.
942			_2lcc _cLE
650		7	_aCáncer _xAspectos genéticos _9273952 _0comprobar BNE19990911214 _2embne
700	1		_aDey, Nandini _eeditor literario _999503 _0Local
700	1		_aDe, Pradip _eeditor literario _999504 _0Local
700	1		_aLeyland-Jones, Brian _eeditor literario _999505 _0Local
830		0	_aCancer Drug Discovery and Development _x2196-9906 _9133188
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-34211-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_aii9783319342115
907			_a.b12953544 _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b10-03-17 _cm _dz _ef _feng _ggw _h0
945			_aRC268.4 .P556 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11596053 _z06-04-17
999			_c86076 _d86076 _x1